Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
NeuroPace ( (NPCE) ) has shared an announcement.
On June 20, 2025, Rebecca Kuhn resigned as NeuroPace‘s Chief Financial Officer and transitioned to a Senior Strategic Advisor role, with a separation agreement outlining her consulting services and severance benefits. Concurrently, Patrick F. Williams was appointed as the new CFO, bringing over 25 years of experience in financial and operational management within public medical device companies, signaling a strategic shift for NeuroPace as it seeks to expand access to its RNS System and enhance its growth trajectory.
The most recent analyst rating on (NPCE) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on NeuroPace stock, see the NPCE Stock Forecast page.
Spark’s Take on NPCE Stock
According to Spark, TipRanks’ AI Analyst, NPCE is a Neutral.
NeuroPace’s overall stock score is primarily impacted by its financial performance challenges, including high leverage and cash flow issues. However, strong earnings call guidance, positive corporate events, and revenue growth potential provide a balanced outlook.
To see Spark’s full report on NPCE stock, click here.
More about NeuroPace
NeuroPace, based in Mountain View, California, is a medical device company focused on improving the lives of people with epilepsy through its RNS System, a brain-responsive platform that provides personalized, real-time treatment at the seizure source. The company aims to offer a better standard of care for patients with drug-resistant epilepsy and potentially other brain disorders.
Average Trading Volume: 303,694
Technical Sentiment Signal: Sell
Current Market Cap: $341.4M
For a thorough assessment of NPCE stock, go to TipRanks’ Stock Analysis page.